Targeted Therapy and Avelumab in Merkel Cell Carcinoma

This study is testing targeted therapy drugs combined with avelumab (an immunotherapy drug) in people with Merkel cell carcinoma — a rare and aggressive type of skin cancer — that has spread to other parts of the body and has not been treated before. **You may be eligible if:** - You are 18 or older with metastatic Merkel cell carcinoma confirmed by biopsy - You have not yet received any systemic (whole-body) therapy for your advanced disease - You have at least one measurable tumor on CT or MRI scans - You are otherwise healthy enough to participate in daily light activities **You may NOT be eligible if:** - You have already received systemic therapy for unresectable or metastatic Merkel cell carcinoma - You have significant organ problems or active autoimmune disease - You are pregnant or not using adequate contraception Talk to your doctor to see if this trial is right for you.